Separate names with a comma.
Please let me know if you know. If you don't know, I would like to hear your opinion. There is an eye medicine in their concept. Can macular...
Don't those prospective drugs contain both a GSK-3 inhibitor and an HDAC inhibitor?
For example, if the contract contains the following text, isn't Astellas entitled as stated in the annual report? "Similarly, if any other...
I wanted to say that the current contract is about FX-322. And by your post, I understand the logic that the parties may be exempt from new...
Enzalutamide (Xtandi) currently sells $3.5 billion annually. It is a drug for prostate cancer. How many FX-*** patients will eventually be in the...
Astellas paid $3 billion when it acquired Audentes Therapeutics. In the future, Astellas will benefit in all countries except the United States...
I hope that FREQ will develop drugs that improve small molecules and gels such as FX-4 **, FX-5 **, and FX-6 **, and ultimately have a better...
What is stated in the annual report means that Astellas has exclusive marketing rights to FX-322 and similar drugs in countries other than the...
Is that your idea? Is it speculation? Did the contract text state that the improved version is also covered? Astellas does not have a patent....
There is a contract that they will be rewarded from Astellas for completion and sale of FX-322. Furthermore, if FX-322 is successful, I think...
I agree. And if the improved gel itself penetrates deeper, I think it will be more effective.
https://investors.frequencytx.com/static-files/bd82e199-8b2c-4c35-9929-3d7ed4cbcfc2 Please read page 15 of the report.
If you want to change the concentration, it will be a different drug and start over from Phase 1. You can avoid "redoing" by starting with a...
[ATTACH] What does "Formulation enabling evaluation of a range of dose levels" mean? Does that mean "FX-345 has different types of...
Was TFI a survey item in Phase 1b? Since there was an anecdote about improving tinnitus, wasn't it adopted as a survey item in Phase 2a?...
